IndraLab

Statements

USP7 inhibits Protease. 1 / 1
| 1
reach
"Expert opinionSelective and reversible inhibitors of ubiquitin specific protease 7 : a patent evaluation (WO2013030218) Benedikt M KesslerUniversity of Oxford, Target Discovery Institute, Nuffield Department of Medicine, Oxford, UKThe invention described in this review (WO2013030218) relates to compounds based on the quinazolin-4-one scaffold, their process of preparation and applications to inhibit the ubiquitin specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunological disorders."
24456106